Active, Not Recruiting
A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)
NCT05526755
- Conditions
- Stage II-IIIB Non-small Cell Lung Carcinoma
- Locations
-
- Research Site Santa Rosa, California, United States
- Research Site Las Vegas, Nevada, United States
- Research Site White Plains, New York, United States
- Research Site Hong Kong